Advertisement
U.S. markets closed
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • Dow 30

    39,087.38
    +90.99 (+0.23%)
     
  • Nasdaq

    16,274.94
    +183.02 (+1.14%)
     
  • Russell 2000

    2,076.39
    +21.55 (+1.05%)
     
  • Crude Oil

    79.81
    +1.55 (+1.98%)
     
  • Gold

    2,091.60
    +36.90 (+1.80%)
     
  • Silver

    23.34
    +0.46 (+2.01%)
     
  • EUR/USD

    1.0839
    +0.0032 (+0.29%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • GBP/USD

    1.2655
    +0.0029 (+0.23%)
     
  • USD/JPY

    150.0640
    +0.0800 (+0.05%)
     
  • Bitcoin USD

    62,004.57
    +495.85 (+0.81%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    39,910.82
    +744.63 (+1.90%)
     

Aspect Biosystems Named to Fast Company’s 2023 List of the Next Big Things in Tech

List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future

VANCOUVER, British Columbia, November 28, 2023--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of disease, today announced that it has been named to Fast Company’s third annual Next Big Things in Tech list, honoring technological breakthroughs that promise to shape the future of industries — from healthcare and security to artificial intelligence and data.

Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue therapeutics that are biologically functional, immune protective, and suitable for surgical implantation. By replacing, repairing, or supplementing biological function inside the body, these therapeutics have the potential to transform the lives of millions of people living with difficult-to-treat diseases. Earlier this year, Aspect announced a precedent-setting partnership with Novo Nordisk worth over US$2.6 billion to develop bioprinted tissue therapeutics for diabetes and obesity.

"We’re honored to accept this recognition from Fast Company," said Tamer Mohamed, CEO and co-founder of Aspect Biosystems. "Aspect is taking a truly disruptive approach to regenerative medicine and the treatment of challenging diseases with our full-stack tissue therapeutic platform, and we’re excited to continue this work to revolutionize the standard of care for patients around the world."

"The Next Big Things in Tech is not just a look around the corner — it's a look around the corner after that," says Brendan Vaughan, editor-in-chief of Fast Company. "These are the products and ideas that will define technological innovation for the rest of this decade and beyond — and solve some of the world's most pressing issues. We are thrilled to honor the organizations that are making them a reality."

Click here to see the final list. The Winter 2023/2024 issue of Fast Company is available online now and will hit newsstands on December 5.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

About Aspect Biosystems

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. The company’s current therapeutic pipeline is focused on metabolic and endocrine diseases such as diabetes, obesity, and congenital liver disorders. Learn more at www.aspectbiosystems.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231128120908/en/

Contacts

Emily Stearney
HDMZ
Aspect.PR@HDMZ.com

Advertisement